{"id":"leteprinim","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["leteprinim potassium","leteprinim"],"offLabel":[],"synonyms":["leteprinim potassium","leteprinim"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"In simple terms, LETEPRINIM is a small molecule that fits into a specific lock in the body, which helps to stop or slow down a particular process that is causing a disease or condition. This lock is a protein, and LETEPRINIM is designed to bind to it in a way that blocks its normal function. By doing so, LETEPRINIM can help to reduce symptoms or prevent the progression of a disease.","oneSentence":"LETEPRINIM is a small molecule that works by binding to a specific target in the body to produce its therapeutic effect.","technicalDetail":"LETEPRINIM is a small molecule that acts through a specific mechanism of action, although the exact target and drug class are unknown. It is likely that LETEPRINIM binds to a specific protein or receptor, which triggers a downstream response that produces its therapeutic effect."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3318","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LETEPRINIM","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LETEPRINIM","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T14:05:39.893518","biosimilars":[],"competitors":[],"genericName":"leteprinim","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00041795","phase":"PHASE2","title":"Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy","status":"COMPLETED","sponsor":"NeoTherapeutics","startDate":"2002-01","conditions":["Peripheral Nervous System Diseases","Chemotherapy-Induced Peripheral Neuropathy"],"enrollment":50,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"NBY3IU407M","CHEBI":"CHEBI:135395","INN_ID":"7814","UMLSCUI":"C2825404","ChEMBL_ID":"CHEMBL2104345","KEGG_DRUG":"D04698","PUBCHEM_CID":"135409548","SECONDARY_CAS_RN":"192564-13-9","MESH_SUPPLEMENTAL_RECORD_UI":"C086241"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":7,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"LETEPRINIM","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LETEPRINIM is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not known if it is FDA approved or off-patent. The approved indications for LETEPRINIM are also unknown. Further information on its pharmacokinetics, such as half-life and bioavailability, is not available. As a result, key safety considerations and generic manufacturers are also unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}